ESSA Pharma Inc. Publishes Shareholder Letter for Fiscal Year 2025
Reuters
Aug 01
<a href="https://laohu8.com/S/EPIX">ESSA Pharma Inc.</a> Publishes Shareholder Letter for Fiscal Year 2025
ESSA Pharma Inc. has issued a letter to shareholders regarding a Business Combination Agreement entered into on July 13, 2025. The agreement involves a transaction where XenoTherapeutics, Inc., through its subsidiary Xeno Acquisition Corp., will acquire all issued and outstanding common shares of ESSA Pharma Inc. The company plans to reduce the capital of its common shares and make a concurrent distribution, subject to approval from the Supreme Court of British Columbia. The letter provides information on the potential tax treatment of the proposed distribution and highlights considerations relevant to shareholders' individual circumstances. More detailed tax information will be available in the proxy statement and management information circular filed with the United States Securities and Exchange Commission. The full letter can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-072771), on July 31, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.